Grifols (GRFS) Competitors $10.78 +0.08 (+0.75%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$10.78 0.00 (0.00%) As of 08/1/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock GRFS vs. BNTX, SMMT, INSM, TEVA, GMAB, RDY, MRNA, QGEN, VTRS, and ASNDShould you be buying Grifols stock or one of its competitors? The main competitors of Grifols include BioNTech (BNTX), Summit Therapeutics (SMMT), Insmed (INSM), Teva Pharmaceutical Industries (TEVA), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Moderna (MRNA), Qiagen (QGEN), Viatris (VTRS), and Ascendis Pharma A/S (ASND). These companies are all part of the "pharmaceutical products" industry. Grifols vs. Its Competitors BioNTech Summit Therapeutics Insmed Teva Pharmaceutical Industries Genmab A/S Dr. Reddy's Laboratories Moderna Qiagen Viatris Ascendis Pharma A/S Grifols (NASDAQ:GRFS) and BioNTech (NASDAQ:BNTX) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, earnings, dividends, institutional ownership, profitability, analyst recommendations, risk and media sentiment. Which has higher valuation and earnings, GRFS or BNTX? Grifols has higher revenue and earnings than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGrifols$7.81B0.95$169.80M$1.179.21BioNTech$2.98B8.67-$719.92M-$3.40-31.57 Does the media prefer GRFS or BNTX? In the previous week, Grifols and Grifols both had 8 articles in the media. BioNTech's average media sentiment score of 0.88 beat Grifols' score of 0.52 indicating that BioNTech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Grifols 2 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioNTech 3 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer GRFS or BNTX? Grifols currently has a consensus price target of $10.30, indicating a potential downside of 4.45%. BioNTech has a consensus price target of $136.58, indicating a potential upside of 27.24%. Given BioNTech's higher probable upside, analysts plainly believe BioNTech is more favorable than Grifols.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Grifols 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.00BioNTech 0 Sell rating(s) 4 Hold rating(s) 13 Buy rating(s) 0 Strong Buy rating(s) 2.76 Is GRFS or BNTX more profitable? Grifols has a net margin of 0.00% compared to BioNTech's net margin of -27.37%. Grifols' return on equity of 0.00% beat BioNTech's return on equity.Company Net Margins Return on Equity Return on Assets GrifolsN/A N/A N/A BioNTech -27.37%-3.94%-3.41% Which has more volatility & risk, GRFS or BNTX? Grifols has a beta of 0.56, indicating that its stock price is 44% less volatile than the S&P 500. Comparatively, BioNTech has a beta of 1.23, indicating that its stock price is 23% more volatile than the S&P 500. Do institutionals & insiders believe in GRFS or BNTX? 15.5% of BioNTech shares are owned by institutional investors. 0.2% of Grifols shares are owned by insiders. Comparatively, 19.2% of BioNTech shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. SummaryGrifols beats BioNTech on 9 of the 16 factors compared between the two stocks. Get Grifols News Delivered to You Automatically Sign up to receive the latest news and ratings for GRFS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GRFS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GRFS vs. The Competition Export to ExcelMetricGrifolsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.41B$2.50B$5.52B$9.37BDividend YieldN/A1.80%4.74%4.12%P/E Ratio9.218.9728.9323.80Price / Sales0.95687.56440.5196.33Price / Cash11.52155.1435.0756.59Price / Book0.864.838.255.54Net Income$169.80M$31.62M$3.25B$259.97M7 Day Performance6.73%-5.28%-3.75%-4.67%1 Month Performance18.79%3.12%2.99%3.29%1 Year Performance42.22%-2.00%25.34%17.92% Grifols Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GRFSGrifols3.2372 of 5 stars$10.78+0.7%$10.30-4.5%+42.2%$7.41B$7.81B9.2123,822Dividend AnnouncementBNTXBioNTech2.7548 of 5 stars$108.91-1.0%$136.58+25.4%+30.9%$26.18B$2.98B-32.036,772Upcoming EarningsGap DownSMMTSummit Therapeutics2.89 of 5 stars$26.34+0.5%$34.67+31.6%+159.9%$19.56B$700K-77.47110Upcoming EarningsINSMInsmed3.7898 of 5 stars$102.78+0.2%$108.47+5.5%+51.4%$19.50B$363.71M-17.271,271Positive NewsUpcoming EarningsTEVATeva Pharmaceutical Industries3.9764 of 5 stars$16.30+1.5%$24.71+51.7%-9.5%$18.69B$16.54B-14.1736,830News CoveragePositive NewsEarnings ReportGMABGenmab A/S3.6315 of 5 stars$21.69-0.9%$37.80+74.3%-22.9%$13.92B$3.12B12.322,682News CoveragePositive NewsUpcoming EarningsShort Interest ↑RDYDr. Reddy's Laboratories2.2883 of 5 stars$14.57+0.6%$16.95+16.4%-16.2%$12.16B$3.81B22.0727,811MRNAModerna4.3952 of 5 stars$30.97-0.9%$46.61+50.5%-68.1%$11.98B$3.24B-3.555,800Trending NewsEarnings ReportAnalyst ForecastOptions VolumeQGENQiagen3.2031 of 5 stars$48.06-0.6%$49.40+2.8%+10.9%$10.68B$1.98B120.495,765News CoverageUpcoming EarningsAnalyst UpgradeVTRSViatris2.2069 of 5 stars$8.90+0.2%$10.40+16.9%-25.8%$10.45B$14.74B-2.8132,000Upcoming EarningsShort Interest ↑ASNDAscendis Pharma A/S3.0649 of 5 stars$168.02-1.1%$223.07+32.8%+31.9%$10.39B$393.54M0.001,017Analyst Forecast Related Companies and Tools Related Companies BNTX Alternatives SMMT Alternatives INSM Alternatives TEVA Alternatives GMAB Alternatives RDY Alternatives MRNA Alternatives QGEN Alternatives VTRS Alternatives ASND Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GRFS) was last updated on 8/3/2025 by MarketBeat.com Staff From Our PartnersMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredEx-Hedge Fund Manager Uncovers $100 Trillion Land ShiftTrump's Radical New Plan Could Enrich Thousands This isn't a campaign stunt. It's a $100 trillion move to u...Stansberry Research | SponsoredInvestigating the Most Controversial Stock on EarthTesla’s wild price swings may not be random after all. Hedge fund veteran Larry Benedict has uncovered a st...Brownstone Research | SponsoredThis New Rule Could Change EverythingA major change is quietly going into effect this July — and Wall Street is already positioning for it. Big ...American Alternative | SponsoredToo busy to trade? Good.Too busy to trade? That might be your edge. This after-hours strategy is built for people who don’t sit at ...Timothy Sykes | SponsoredSell these "safe" blue chips immediatelyInvesting Legend Hints the End May be Near for These 3 Iconic Stocks One company to replace Amazon… another...InvestorPlace | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Grifols, S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Grifols With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.